Beta
388345

Ultra-low-dose naloxone added to fentanyl and lidocaine for peribulbar anesthesia: A randomized controlled trial

Article

Last updated: 05 Jan 2025

Subjects

-

Tags

-

Abstract

Purpose
Purpose was to evaluate the quality of the block and the duration of postoperative analgesia when ultra-low-dose of naloxone added to fentanyl and lidocaine for peribulbar anesthesia.
Methods
Sixty adult patients of both sexes, ASA I and II scheduled for open globe cataract surgery in the Ophthalmology Department Tanta University Hospital were included in this randomized prospective clinical trial.
Results
The time to first rescue analgesic was significantly longer in group II (7.73 ± 0.98) than group I (4.30 ± 0.47). The IOP was increased significantly at 2 min post-injection then, it became insignificant at 10 min postinjection compared to the preinjection values in both groups. There were few minor complications with no significant difference between groups.
Conclusion
Addition of ultra-low-dose naloxone to fentanyl and lidocaine for peribulbar anesthesia prolongs the duration of postoperative analgesia without increasing the adverse effects.

DOI

10.1016/j.egja.2014.12.005

Authors

First Name

Hoda Alsaid Ahmed

Last Name

Ezz

MiddleName

-

Affiliation

-

Email

-

City

-

Orcid

-

First Name

Rehab Said

Last Name

Elkala

MiddleName

-

Affiliation

-

Email

-

City

-

Orcid

-

Volume

31

Article Issue

2

Related Issue

51190

Issue Date

2015-04-01

Receive Date

2014-08-22

Publish Date

2015-04-01

Page Start

161

Page End

165

Print ISSN

1110-1849

Online ISSN

1687-1804

Link

https://egja.journals.ekb.eg/article_388345.html

Detail API

https://egja.journals.ekb.eg/service?article_code=388345

Order

388,345

Publication Type

Journal

Publication Title

Egyptian Journal of Anaesthesia

Publication Link

https://egja.journals.ekb.eg/

MainTitle

Ultra-low-dose naloxone added to fentanyl and lidocaine for peribulbar anesthesia: A randomized controlled trial

Details

Type

Article

Created At

21 Dec 2024